Treatment of myelodysplastic syndromes with 2-o and, or 3-o desulfated heparinoids

Abstract

Methods are presented for treating cancers and hematopoietic stem cell disorders, comprising administering to a subject with a cancer or hematopoietic stem cell disorder who is receiving a treatment regimen, a heparin derivative capable of inhibiting, reducing, abrogating or otherwise interfering with the binding of CXCL12 to CXCR4, wherein the cancer or hematopoietic stem cell disorder is one in which interaction of CXCL12 with CXCR4 privileges the cancer or disordered HSCs against therapeutic intervention. In preferred embodiments, the heparin derivative is a substantially 2-O, 3-O-desulfated heparin derivative.

1 . (canceled) 
     
     
         2 . A method of treating acute myeloid leukemia (AML), comprising:
 adjunctively administering to a subject with AML who is receiving a hypomethylating agent a heparinoid that is substantially desulfated at the 2-O position and/or 3-O position, in an amount and at a time effective to enhance effectiveness of the hypomethylating agent.   
     
     
         3 . The method of  claim 2 , wherein the hypomethylating agent is azacitidine. 
     
     
         4 . The method of  claim 2 , wherein the heparinoid is at least 85% desulfated at the 2-O position. 
     
     
         5 . The method of  claim 2 , wherein the heparinoid is at least 85% desulfated at the 3-O position. 
     
     
         6 . The method of  claim 2 , wherein the heparinoid has an average molecular weight of about 8 kDa to about 15 kDa. 
     
     
         7 . The method of  claim 2 , wherein the heparinoid is administered subcutaneously. 
     
     
         8 . The method of  claim 2 , wherein the heparinoid is administered intravenously. 
     
     
         9 . The method of  claim 8 , wherein the heparinoid is administered as one or more bolus injections. 
     
     
         10 . The method of  claim 9 , wherein the bolus dose is 2 mg/kg-25 mg/kg. 
     
     
         11 . The method of  claim 8 , wherein the heparinoid is administered as a continuous infusion. 
     
     
         12 . The method of  claim 11 , wherein the continuous infusion is administered at a dose of 0.1 mg/kg/hr-5 mg/kg/hr. 
     
     
         13 . The method of  claim 8 , wherein the heparinoid is administered as a bolus injection followed by continuous infusion. 
     
     
         14 . The method of  claim 13 , wherein the heparinoid is administered as a 4 mg/kg bolus followed by a continuous infusion of 0.25 mg/kg/hr. 
     
     
         15 . The method of  claim 2 , wherein the heparinoid is administered prior to the hypomethylating agent. 
     
     
         16 . The method of  claim 2 , wherein the heparinoid is administered in combination with the hypomethylating agent. 
     
     
         17 . The method of  claim 16 , wherein the heparinoid is administered in combination with azacitidine. 
     
     
         18 . The method of  claim 17 , wherein the azacitidine is administered intravenously at a dose of 5 mg/m 2 -500 mg/m 2 . 
     
     
         19 . The method of  claim 18 , wherein the heparinoid is administered as a bolus injection at a dose of 4 mg/kg followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hr;
 and wherein azacitidine is administered at a dose of 75 mg/m 2  as a 15 minute intravenous infusion.   
     
     
         20 . A method of treating acute myeloid leukemia (AML), comprising:
 administering azacitidine and a heparinoid substantially desulfated at the 2-O position and/or 3-O position to a subject with AML,   wherein the azacitidine is administered as an intravenous infusion at a dose of 75 mg/m 2  as a 15 minute intravenous infusion daily on Days 1 through 7 of the at least one 28-day cycle; and   wherein the heparinoid is administered as a bolus injection at a dose of 4 mg/kg on Day 1 followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hr for Days 1 through 7 of at least one 28-day cycle.